The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Changes In Market Value Are Expected For The Epitranscriptomic Therapies Market Over The 2026–2030 Period?
The epitranscriptomic therapies market has experienced rapid expansion over the past few years. It is anticipated to increase from $1.56 billion in 2025 to $1.9 billion in 2026, with a compound annual growth rate (CAGR) of 21.6%. Historically, this growth was fueled by breakthroughs in RNA biology research, an improved understanding of gene regulation mechanisms, the scaling up of oncology research programs, the accessibility of advanced sequencing technologies, and an increase in translational medicine initiatives.
The epitranscriptomic therapies market is projected to experience substantial expansion over the upcoming years. This market is anticipated to reach a valuation of $4.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 21.9%. The expansion during the projected timeframe stems from various factors, including heightened investments in RNA-based therapeutics, a growing need for targeted cancer treatments, the broadening of personalized medicine strategies, an uptick in clinical trial endeavors within epitranscriptomics, and augmented regulatory involvement concerning innovative RNA therapies. Key trends anticipated for this forecast period encompass the escalating development of epitranscriptomic drug pipelines, the increasing adoption of RNA modification profiling tools, the proliferation of combination epitranscriptomic therapies, the expanding incorporation of bioinformatics into therapy design, and a heightened emphasis on precision medicine applications.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=33108&type=smp
Which Drivers Are Supporting The Epitranscriptomic Therapies Market Growth?
The increasing demand for personalized medicine is expected to propel the growth of the epitranscriptomic therapies market going forward. Personalized medicine refers to a medical approach that tailors healthcare decisions, treatments, and interventions to the individual characteristics of each patient, such as their genetic profile, lifestyle, and environment. This heightened demand for personalized medicine primarily stems from the rising prevalence of chronic and complex diseases, as tailored treatments can more effectively target individual patient needs and improve outcomes. Personalized medicine supports epitranscriptomic therapies by customizing treatments to an individual’s specific RNA modification patterns, thereby enhancing therapeutic effectiveness and reducing the risk of adverse effects. For instance, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare disease patients, a notable increase from six in 2022. The newly approved personalized treatments for 2023 also included seven cancer drugs and three for other diseases and conditions. Therefore, the increasing demand for personalized medicine is driving the growth of the epitranscriptomic therapies market.
Which Segments Define The Epitranscriptomic Therapies Market Segment Structure?
The epitranscriptomic therapies market covered in this report is segmented –
1) By Therapy Type: Small Molecule Inhibitors; Ribonucleic Acid Modifying Enzymes; Antisense Oligonucleotides; Other Therapy Types
2) By Route of Administration: Injectable; Oral; Other Routes Of Administration
3) By Application: Cancer; Neurological Disorders; Metabolic Diseases; Infectious Diseases; Other Applications
4) By End-User: Hospitals; Research Institutes; Pharmaceutical And Biotechnology Companies; Other End-Users
Subsegments:
1) By Small Molecule Inhibitors: Methyltransferase Inhibitors; Demethylase Inhibitors; Reader Protein Inhibitors; Writer Enzyme Inhibitors; Eraser Enzyme Inhibitors
2) By Ribonucleic Acid Modifying Enzymes: Methyltransferase Enzymes; Demethylase Enzymes; Pseudouridine Synthase Enzymes; Adenosine Deaminase Enzymes; Cytidine Deaminase Enzymes
3) By Antisense Oligonucleotides: Gapmer Oligonucleotides; Splice Modulating Oligonucleotides; Translation Blocking Oligonucleotides; Exon Skipping Oligonucleotides; Gene Expression Silencing Oligonucleotides
4) By Other Therapy Types: Ribonucleic Acid Interference Based Therapies; Messenger Ribonucleic Acid Editing Therapies; Epitranscriptomic Vaccine Platforms; Gene Regulation Modulation Therapies; Combination Epitranscriptomic Therapies
Which Trends Are Expected To Impact The Epitranscriptomic Therapies Market?
Leading companies in the epitranscriptomic therapies market are prioritizing the formation of strategic alliances to develop novel RNA-modifying cancer treatments. Strategic partnerships involve cooperative frameworks where organizations pool resources, knowledge, or strengths to pursue mutual objectives that foster quicker growth, reduce operational risks, and boost market competitiveness. For example, in January 2026, STORM Therapeutics Ltd., a biotechnology company based in the UK, collaborated with Alida Biosciences Inc., a US-based technology company, to further cancer therapies specifically targeting epitranscriptomic mechanisms. This collaboration is centered on integrating AlidaBio’s EpiPlex and EpiScout platforms with STORM’s clinical trials of STC-15, a pioneering METTL3 inhibitor. The partnership intends to identify and validate m6A RNA modification biomarkers that can predict patient outcomes and optimize therapeutic plans. This joint effort combines drug development with advanced RNA profiling, representing a significant progression in epitranscriptomic cancer therapies.
Who Are The Established Players Within The Epitranscriptomic Therapies Market?
Major companies operating in the epitranscriptomic therapies market are AstraZeneca PLC, GSK plc, Moderna Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Arcturus Therapeutics Holdings Inc., Arrakis Therapeutics Inc., AIRNA Corporation, CD Genomics, ProQR Therapeutics N.V., Nimbus Therapeutics LLC, Envisagenics Inc., Skyhawk Therapeutics Inc., Avidity Biosciences Inc., STORM Therapeutics Ltd., Omega Therapeutics Inc., Korro Bio Inc., Accent Therapeutics Inc., Alida Biosciences Inc., and O2nix Bio.
Get The Full Epitranscriptomic Therapies Market Report:
https://www.thebusinessresearchcompany.com/report/epitranscriptomic-therapies-market-report
Which Region Is The Leading Market For The Epitranscriptomic Therapies Market?
North America was the largest region in the epitranscriptomic therapies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epitranscriptomic therapies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Epitranscriptomic Therapies Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/customise?id=33108&type=smp
Browse Through More Reports Similar to the Global Epitranscriptomic Therapies Market 2026, By The Business Research Company
Ecoa Esource And Clinical Trials Market Report 2026
Epilepsy Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model